GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow for the year ending March 31, 2025: USD 150.95 M

GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow is USD 150.95 M for the year ending March 31, 2025, a 116.32% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow for the year ending March 31, 2024 was USD 69.78 M, a 18.44% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow for the year ending March 31, 2023 was USD 58.92 M, a -44.82% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow for the year ending March 31, 2022 was USD 106.78 M, a 35.28% change year over year.
  • GlaxoSmithKline Pharmaceuticals Limited Operating Cash Flow for the year ending March 31, 2021 was USD 78.93 M, a 21.26% change year over year.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities